Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 100 | 2024 | 20822 | 3.860 |
Why?
|
Mastectomy, Segmental | 31 | 2023 | 956 | 3.520 |
Why?
|
Inflammatory Breast Neoplasms | 14 | 2024 | 143 | 2.910 |
Why?
|
Radiotherapy, Adjuvant | 26 | 2023 | 1770 | 2.690 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 10 | 2023 | 949 | 2.150 |
Why?
|
Neoplasm Recurrence, Local | 37 | 2022 | 9239 | 2.120 |
Why?
|
Mastectomy | 26 | 2023 | 1793 | 2.050 |
Why?
|
Carcinoma, Ductal, Breast | 12 | 2020 | 1101 | 1.610 |
Why?
|
Wine | 7 | 2019 | 165 | 1.570 |
Why?
|
Saccharomyces | 5 | 2015 | 65 | 1.500 |
Why?
|
Receptor, erbB-2 | 18 | 2024 | 2416 | 0.990 |
Why?
|
Neoadjuvant Therapy | 15 | 2024 | 2728 | 0.990 |
Why?
|
Sentinel Lymph Node Biopsy | 14 | 2023 | 709 | 0.940 |
Why?
|
Lymphatic Metastasis | 19 | 2023 | 2924 | 0.900 |
Why?
|
Radiation Oncology | 6 | 2023 | 555 | 0.880 |
Why?
|
Lymph Node Excision | 12 | 2023 | 1261 | 0.880 |
Why?
|
Radiation Injuries | 4 | 2021 | 1180 | 0.860 |
Why?
|
Paclitaxel | 7 | 2024 | 1708 | 0.860 |
Why?
|
Thoracic Wall | 3 | 2018 | 203 | 0.690 |
Why?
|
Lymph Nodes | 11 | 2021 | 3474 | 0.680 |
Why?
|
Chemotherapy, Adjuvant | 18 | 2023 | 3479 | 0.660 |
Why?
|
Dermatomyositis | 1 | 2021 | 224 | 0.660 |
Why?
|
Mammary Neoplasms, Animal | 1 | 2018 | 137 | 0.590 |
Why?
|
Lymphedema | 2 | 2023 | 534 | 0.580 |
Why?
|
Axilla | 13 | 2023 | 595 | 0.580 |
Why?
|
Chimera | 2 | 2015 | 485 | 0.560 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2020 | 806 | 0.550 |
Why?
|
Carcinoma in Situ | 2 | 2020 | 806 | 0.550 |
Why?
|
Heart | 2 | 2022 | 4467 | 0.540 |
Why?
|
Benchmarking | 1 | 2022 | 1042 | 0.540 |
Why?
|
Fermentation | 3 | 2019 | 144 | 0.530 |
Why?
|
Combined Modality Therapy | 18 | 2021 | 8642 | 0.530 |
Why?
|
Food Microbiology | 1 | 2015 | 78 | 0.520 |
Why?
|
Neoplasm Staging | 21 | 2023 | 11031 | 0.520 |
Why?
|
Mediastinal Neoplasms | 1 | 2018 | 423 | 0.510 |
Why?
|
Hybridization, Genetic | 2 | 2013 | 109 | 0.500 |
Why?
|
Cisplatin | 1 | 2021 | 1662 | 0.500 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 15 | 2024 | 11524 | 0.490 |
Why?
|
Female | 109 | 2024 | 380194 | 0.480 |
Why?
|
Brachytherapy | 4 | 2023 | 1248 | 0.470 |
Why?
|
Lymphatic Irradiation | 3 | 2014 | 103 | 0.460 |
Why?
|
Carcinoma | 3 | 2017 | 2375 | 0.460 |
Why?
|
Breast | 4 | 2023 | 1969 | 0.460 |
Why?
|
Neoplasm, Residual | 7 | 2022 | 973 | 0.460 |
Why?
|
Carcinoma, Lobular | 5 | 2020 | 484 | 0.450 |
Why?
|
Fluorouracil | 3 | 2014 | 1619 | 0.430 |
Why?
|
Premenopause | 2 | 2016 | 1033 | 0.430 |
Why?
|
Radiotherapy Dosage | 9 | 2021 | 2879 | 0.390 |
Why?
|
Receptors, Estrogen | 15 | 2022 | 2187 | 0.390 |
Why?
|
Mammography | 8 | 2013 | 2476 | 0.390 |
Why?
|
Cyclophosphamide | 5 | 2017 | 2242 | 0.380 |
Why?
|
Humans | 119 | 2024 | 744343 | 0.370 |
Why?
|
Wound Healing | 1 | 2021 | 2785 | 0.360 |
Why?
|
Saccharomyces cerevisiae | 5 | 2019 | 2752 | 0.360 |
Why?
|
Middle Aged | 61 | 2023 | 213383 | 0.350 |
Why?
|
Research | 1 | 2018 | 1999 | 0.350 |
Why?
|
Receptors, Progesterone | 10 | 2020 | 1097 | 0.340 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2015 | 1624 | 0.330 |
Why?
|
Fluorodeoxyglucose F18 | 4 | 2020 | 2016 | 0.320 |
Why?
|
Methotrexate | 2 | 2005 | 1727 | 0.310 |
Why?
|
Aged, 80 and over | 26 | 2021 | 57776 | 0.310 |
Why?
|
Mastectomy, Modified Radical | 3 | 2017 | 62 | 0.270 |
Why?
|
Aged | 42 | 2021 | 163280 | 0.260 |
Why?
|
Adult | 49 | 2021 | 214055 | 0.250 |
Why?
|
Pain Measurement | 1 | 2014 | 3420 | 0.240 |
Why?
|
Follow-Up Studies | 19 | 2020 | 39050 | 0.230 |
Why?
|
Salvage Therapy | 4 | 2015 | 1275 | 0.230 |
Why?
|
Radiotherapy | 4 | 2018 | 1533 | 0.220 |
Why?
|
Retrospective Studies | 27 | 2022 | 77449 | 0.220 |
Why?
|
Mammaplasty | 5 | 2019 | 1204 | 0.220 |
Why?
|
Radiation-Sensitizing Agents | 2 | 2005 | 358 | 0.220 |
Why?
|
Taste | 2 | 2015 | 176 | 0.210 |
Why?
|
Imaging, Three-Dimensional | 1 | 2015 | 4042 | 0.200 |
Why?
|
Tomography, Emission-Computed | 2 | 2004 | 1144 | 0.200 |
Why?
|
Disease-Free Survival | 5 | 2016 | 6895 | 0.200 |
Why?
|
Risk | 6 | 2023 | 9687 | 0.190 |
Why?
|
Doxorubicin | 3 | 2014 | 2234 | 0.190 |
Why?
|
Tamoxifen | 3 | 2013 | 981 | 0.180 |
Why?
|
Radiotherapy, Conformal | 1 | 2023 | 548 | 0.180 |
Why?
|
Ataxia Telangiectasia | 1 | 2021 | 112 | 0.180 |
Why?
|
Brain Neoplasms | 4 | 2017 | 8863 | 0.180 |
Why?
|
Cone-Beam Computed Tomography | 4 | 2012 | 450 | 0.180 |
Why?
|
Treatment Outcome | 17 | 2024 | 63114 | 0.180 |
Why?
|
Nitriles | 2 | 2024 | 956 | 0.180 |
Why?
|
Body Mass Index | 2 | 2020 | 12720 | 0.180 |
Why?
|
Taxoids | 2 | 2017 | 666 | 0.170 |
Why?
|
Thorax | 1 | 2022 | 547 | 0.170 |
Why?
|
Pubic Bone | 1 | 1999 | 29 | 0.170 |
Why?
|
Naphthalenes | 1 | 2019 | 194 | 0.160 |
Why?
|
Maximum Tolerated Dose | 1 | 2021 | 892 | 0.160 |
Why?
|
Survival Analysis | 6 | 2019 | 10252 | 0.160 |
Why?
|
Withholding Treatment | 1 | 2023 | 599 | 0.160 |
Why?
|
Decision Making | 3 | 2020 | 3887 | 0.160 |
Why?
|
Vitis | 2 | 2019 | 18 | 0.160 |
Why?
|
Patient Advocacy | 1 | 2020 | 353 | 0.160 |
Why?
|
Prospective Studies | 11 | 2023 | 53288 | 0.160 |
Why?
|
Survival Rate | 6 | 2019 | 12788 | 0.160 |
Why?
|
Central Nervous System Neoplasms | 2 | 2022 | 895 | 0.150 |
Why?
|
Antineoplastic Agents, Hormonal | 4 | 2013 | 1524 | 0.150 |
Why?
|
Patient Selection | 4 | 2021 | 4215 | 0.150 |
Why?
|
Zimbabwe | 3 | 2021 | 129 | 0.150 |
Why?
|
Treatment Failure | 3 | 2015 | 2618 | 0.150 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 2 | 2015 | 1184 | 0.140 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2021 | 547 | 0.140 |
Why?
|
Ideal Body Weight | 1 | 2016 | 27 | 0.140 |
Why?
|
Lung | 1 | 2015 | 9856 | 0.140 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2000 | 624 | 0.140 |
Why?
|
Radiopharmaceuticals | 3 | 2020 | 2645 | 0.130 |
Why?
|
Acetic Acid | 1 | 2015 | 55 | 0.130 |
Why?
|
Polymorphism, Restriction Fragment Length | 3 | 2013 | 768 | 0.130 |
Why?
|
Appointments and Schedules | 1 | 2019 | 417 | 0.130 |
Why?
|
Neoplasm Invasiveness | 5 | 2019 | 3616 | 0.130 |
Why?
|
Obesity | 2 | 2023 | 12745 | 0.130 |
Why?
|
Patient Care | 1 | 2021 | 640 | 0.130 |
Why?
|
Inhalation | 1 | 2015 | 143 | 0.130 |
Why?
|
Interdisciplinary Communication | 1 | 2021 | 950 | 0.130 |
Why?
|
Patient Care Planning | 1 | 2020 | 921 | 0.120 |
Why?
|
Extremities | 1 | 2020 | 865 | 0.120 |
Why?
|
Neoplasms, Second Primary | 2 | 2021 | 1061 | 0.120 |
Why?
|
Tomography, X-Ray Computed | 6 | 2020 | 20129 | 0.120 |
Why?
|
Carbohydrate Metabolism | 1 | 2015 | 264 | 0.120 |
Why?
|
Color | 1 | 2015 | 307 | 0.120 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2016 | 255 | 0.120 |
Why?
|
Polymerase Chain Reaction | 3 | 2013 | 6171 | 0.120 |
Why?
|
Volatilization | 1 | 2013 | 82 | 0.110 |
Why?
|
Pyrazoles | 1 | 2024 | 1972 | 0.110 |
Why?
|
Crosses, Genetic | 2 | 2013 | 791 | 0.110 |
Why?
|
Regression Analysis | 2 | 2014 | 6459 | 0.110 |
Why?
|
Organs at Risk | 1 | 2015 | 346 | 0.110 |
Why?
|
Chromosomes, Fungal | 1 | 2013 | 111 | 0.110 |
Why?
|
Germ-Line Mutation | 1 | 2021 | 1788 | 0.110 |
Why?
|
Peptide Elongation Factor G | 1 | 2012 | 12 | 0.110 |
Why?
|
Recombination, Genetic | 2 | 2012 | 1586 | 0.110 |
Why?
|
Thinness | 1 | 2016 | 480 | 0.110 |
Why?
|
Benzimidazoles | 1 | 2018 | 850 | 0.110 |
Why?
|
Peptide Elongation Factors | 1 | 2012 | 62 | 0.110 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2019 | 934 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2021 | 9959 | 0.100 |
Why?
|
Patient Preference | 1 | 2019 | 890 | 0.100 |
Why?
|
DNA, Ribosomal | 1 | 2013 | 290 | 0.100 |
Why?
|
Solvents | 1 | 2013 | 302 | 0.100 |
Why?
|
Tumor Burden | 2 | 2015 | 1915 | 0.100 |
Why?
|
Flavoring Agents | 1 | 2012 | 52 | 0.100 |
Why?
|
Cell Respiration | 1 | 2012 | 201 | 0.100 |
Why?
|
Pyrimidines | 1 | 2024 | 2942 | 0.100 |
Why?
|
Rectal Neoplasms | 1 | 2021 | 1206 | 0.100 |
Why?
|
Ultrasonography, Mammary | 1 | 2013 | 250 | 0.100 |
Why?
|
Hydrogen Sulfide | 1 | 2012 | 137 | 0.100 |
Why?
|
Estrogen Receptor alpha | 1 | 2015 | 577 | 0.100 |
Why?
|
Radiation Dosage | 4 | 2011 | 1928 | 0.100 |
Why?
|
Food Industry | 1 | 2011 | 68 | 0.090 |
Why?
|
Risk Factors | 11 | 2023 | 72290 | 0.090 |
Why?
|
Patient Compliance | 1 | 2021 | 2684 | 0.090 |
Why?
|
Fluorescence | 1 | 2013 | 751 | 0.090 |
Why?
|
Heptanoic Acids | 1 | 2012 | 343 | 0.090 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 640 | 0.090 |
Why?
|
Body Burden | 1 | 2010 | 158 | 0.090 |
Why?
|
Deoxycytidine | 1 | 2014 | 826 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 3 | 2015 | 6538 | 0.090 |
Why?
|
Quality of Life | 3 | 2020 | 12804 | 0.090 |
Why?
|
Scattering, Radiation | 1 | 2011 | 498 | 0.090 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2013 | 1572 | 0.080 |
Why?
|
Medical Oncology | 1 | 2021 | 2265 | 0.080 |
Why?
|
Mastectomy, Extended Radical | 1 | 2008 | 3 | 0.080 |
Why?
|
Palliative Care | 3 | 2021 | 3493 | 0.080 |
Why?
|
Beverages | 2 | 2013 | 820 | 0.080 |
Why?
|
Surgical Instruments | 1 | 2011 | 395 | 0.080 |
Why?
|
Prognosis | 11 | 2022 | 29063 | 0.080 |
Why?
|
Time Factors | 6 | 2021 | 40075 | 0.080 |
Why?
|
Temperature | 1 | 2015 | 2206 | 0.080 |
Why?
|
Species Specificity | 1 | 2013 | 2478 | 0.080 |
Why?
|
Drug Administration Schedule | 4 | 2020 | 4933 | 0.080 |
Why?
|
Metabolic Networks and Pathways | 1 | 2012 | 783 | 0.080 |
Why?
|
Young Adult | 6 | 2021 | 56430 | 0.080 |
Why?
|
Radionuclide Imaging | 2 | 2008 | 2031 | 0.070 |
Why?
|
Phenotype | 3 | 2015 | 16365 | 0.070 |
Why?
|
Postmenopause | 1 | 2016 | 2461 | 0.070 |
Why?
|
Analgesics | 1 | 2014 | 1040 | 0.070 |
Why?
|
Quinazolines | 1 | 2013 | 1356 | 0.070 |
Why?
|
Pandemics | 3 | 2023 | 8388 | 0.070 |
Why?
|
Prostatic Neoplasms | 2 | 2021 | 11124 | 0.070 |
Why?
|
Radiographic Image Enhancement | 1 | 2011 | 885 | 0.070 |
Why?
|
Saccharomycetales | 1 | 2007 | 67 | 0.070 |
Why?
|
Radiation Protection | 1 | 2010 | 419 | 0.070 |
Why?
|
Discriminant Analysis | 1 | 2006 | 235 | 0.070 |
Why?
|
Nomograms | 1 | 2008 | 228 | 0.070 |
Why?
|
Confidence Intervals | 1 | 2012 | 2971 | 0.070 |
Why?
|
Image Processing, Computer-Assisted | 3 | 2012 | 8949 | 0.070 |
Why?
|
Pyrroles | 1 | 2012 | 1146 | 0.070 |
Why?
|
Carboplatin | 2 | 2022 | 801 | 0.070 |
Why?
|
Antineoplastic Agents | 3 | 2020 | 13695 | 0.070 |
Why?
|
Genetic Engineering | 1 | 2011 | 951 | 0.060 |
Why?
|
Overweight | 1 | 2016 | 2371 | 0.060 |
Why?
|
Activities of Daily Living | 1 | 2014 | 2418 | 0.060 |
Why?
|
Radiometry | 1 | 2010 | 800 | 0.060 |
Why?
|
Saccharomyces cerevisiae Proteins | 2 | 2012 | 1888 | 0.060 |
Why?
|
Analysis of Variance | 4 | 2011 | 6365 | 0.060 |
Why?
|
Mammary Arteries | 1 | 2004 | 70 | 0.060 |
Why?
|
Thoracic Vertebrae | 1 | 2008 | 608 | 0.060 |
Why?
|
Practice Guidelines as Topic | 4 | 2016 | 7279 | 0.060 |
Why?
|
Mediastinum | 1 | 2004 | 267 | 0.060 |
Why?
|
Evidence-Based Medicine | 2 | 2012 | 3610 | 0.050 |
Why?
|
Flow Cytometry | 1 | 2013 | 5974 | 0.050 |
Why?
|
Patient Care Team | 1 | 2013 | 2531 | 0.050 |
Why?
|
Genotype | 2 | 2015 | 12951 | 0.050 |
Why?
|
Age Factors | 6 | 2021 | 18370 | 0.050 |
Why?
|
Fast Neutrons | 1 | 2001 | 18 | 0.050 |
Why?
|
Decision Support Techniques | 2 | 2013 | 1956 | 0.050 |
Why?
|
Spinal Neoplasms | 1 | 2008 | 760 | 0.050 |
Why?
|
Neoplasms, Connective Tissue | 1 | 2001 | 40 | 0.050 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2006 | 721 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 1 | 2007 | 1683 | 0.050 |
Why?
|
Vesicular Transport Proteins | 1 | 2003 | 377 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 3 | 2021 | 35421 | 0.050 |
Why?
|
Proportional Hazards Models | 4 | 2021 | 12354 | 0.050 |
Why?
|
Risk Assessment | 3 | 2021 | 23338 | 0.050 |
Why?
|
Health Services Misuse | 1 | 2021 | 243 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2015 | 9438 | 0.040 |
Why?
|
Mitochondria | 1 | 2012 | 3520 | 0.040 |
Why?
|
Cicatrix | 1 | 2005 | 764 | 0.040 |
Why?
|
Models, Theoretical | 1 | 2011 | 3589 | 0.040 |
Why?
|
Cancer Care Facilities | 1 | 2021 | 402 | 0.040 |
Why?
|
Disease Progression | 1 | 2015 | 13284 | 0.040 |
Why?
|
Administration, Oral | 2 | 2018 | 3913 | 0.040 |
Why?
|
Tissue Expansion Devices | 1 | 2019 | 156 | 0.040 |
Why?
|
Disease Management | 2 | 2019 | 2459 | 0.040 |
Why?
|
Membrane Transport Proteins | 1 | 2003 | 1028 | 0.040 |
Why?
|
Software | 1 | 2012 | 4443 | 0.040 |
Why?
|
Perineum | 1 | 1999 | 211 | 0.040 |
Why?
|
Standard of Care | 1 | 2021 | 564 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2011 | 12245 | 0.040 |
Why?
|
Breast Implantation | 1 | 2019 | 218 | 0.040 |
Why?
|
Comparative Effectiveness Research | 1 | 2021 | 681 | 0.030 |
Why?
|
Reactive Oxygen Species | 1 | 2023 | 2077 | 0.030 |
Why?
|
Diagnosis, Differential | 3 | 2020 | 12959 | 0.030 |
Why?
|
Neoplasm Metastasis | 2 | 2021 | 4851 | 0.030 |
Why?
|
Immunoconjugates | 1 | 2022 | 901 | 0.030 |
Why?
|
Anthracyclines | 1 | 2017 | 288 | 0.030 |
Why?
|
Central Nervous System | 1 | 2022 | 1357 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2274 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2005 | 5078 | 0.030 |
Why?
|
Reoperation | 2 | 2017 | 4201 | 0.030 |
Why?
|
Heterozygote | 1 | 2021 | 2804 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2024 | 2938 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2024 | 3200 | 0.030 |
Why?
|
Fruit | 1 | 2019 | 1142 | 0.030 |
Why?
|
United States | 4 | 2023 | 69872 | 0.030 |
Why?
|
Kinetics | 1 | 2021 | 6473 | 0.030 |
Why?
|
Infection Control | 1 | 2021 | 966 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2014 | 25043 | 0.030 |
Why?
|
DNA, Fungal | 2 | 2007 | 280 | 0.030 |
Why?
|
Hormones | 1 | 2017 | 889 | 0.030 |
Why?
|
Odds Ratio | 2 | 2017 | 9849 | 0.030 |
Why?
|
Breast Implants | 1 | 2016 | 387 | 0.030 |
Why?
|
Glucose | 2 | 2003 | 4397 | 0.030 |
Why?
|
Incidence | 2 | 2022 | 20947 | 0.030 |
Why?
|
Neoplasms | 1 | 2001 | 21683 | 0.030 |
Why?
|
Soft Tissue Neoplasms | 1 | 2001 | 1363 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2021 | 2564 | 0.020 |
Why?
|
Postoperative Period | 1 | 2016 | 1842 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2018 | 1405 | 0.020 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2014 | 415 | 0.020 |
Why?
|
Cohort Studies | 4 | 2017 | 40561 | 0.020 |
Why?
|
Air | 1 | 2011 | 182 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2008 | 6364 | 0.020 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 7913 | 0.020 |
Why?
|
Male | 5 | 2021 | 350118 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2003 | 5021 | 0.020 |
Why?
|
Animals | 2 | 2018 | 168757 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2018 | 2309 | 0.020 |
Why?
|
Sarcoma | 1 | 2001 | 1897 | 0.020 |
Why?
|
Technology, Radiologic | 1 | 2009 | 163 | 0.020 |
Why?
|
Automation | 1 | 2011 | 584 | 0.020 |
Why?
|
Neutropenia | 1 | 2014 | 895 | 0.020 |
Why?
|
Ribosomes | 1 | 2012 | 500 | 0.020 |
Why?
|
Remission Induction | 1 | 2014 | 2386 | 0.020 |
Why?
|
Xanthenes | 1 | 2007 | 73 | 0.020 |
Why?
|
Mutagenesis | 1 | 2012 | 1266 | 0.020 |
Why?
|
Estrogen Antagonists | 1 | 2008 | 152 | 0.020 |
Why?
|
Gestational Age | 1 | 2016 | 3493 | 0.020 |
Why?
|
RNA, Ribosomal, 5.8S | 1 | 2007 | 4 | 0.020 |
Why?
|
Consensus | 1 | 2016 | 2959 | 0.020 |
Why?
|
Fatigue | 1 | 2014 | 1531 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2019 | 3396 | 0.020 |
Why?
|
DNA Fingerprinting | 1 | 2007 | 112 | 0.020 |
Why?
|
Radiology | 1 | 2021 | 2100 | 0.020 |
Why?
|
Immunotherapy | 1 | 2022 | 4445 | 0.020 |
Why?
|
Cell Death | 1 | 2012 | 1706 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2003 | 7880 | 0.020 |
Why?
|
Algorithms | 2 | 2021 | 13881 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2014 | 1179 | 0.020 |
Why?
|
Least-Squares Analysis | 1 | 2006 | 379 | 0.020 |
Why?
|
Sequence Analysis, Protein | 1 | 2007 | 258 | 0.020 |
Why?
|
Radiation Pneumonitis | 1 | 2005 | 104 | 0.020 |
Why?
|
Poisson Distribution | 1 | 2006 | 513 | 0.020 |
Why?
|
Preoperative Care | 1 | 2014 | 2250 | 0.020 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2008 | 604 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2012 | 15076 | 0.010 |
Why?
|
Markov Chains | 1 | 2007 | 969 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5137 | 0.010 |
Why?
|
Australia | 1 | 2007 | 1170 | 0.010 |
Why?
|
Genetic Complementation Test | 1 | 2003 | 562 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2012 | 3505 | 0.010 |
Why?
|
Therapy, Computer-Assisted | 1 | 2005 | 274 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2020 | 21746 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2008 | 15165 | 0.010 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2006 | 506 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10943 | 0.010 |
Why?
|
Beer | 1 | 2002 | 127 | 0.010 |
Why?
|
Polyploidy | 1 | 2002 | 114 | 0.010 |
Why?
|
Malus | 1 | 2002 | 48 | 0.010 |
Why?
|
Perception | 1 | 2008 | 1198 | 0.010 |
Why?
|
Reproducibility of Results | 2 | 2011 | 19905 | 0.010 |
Why?
|
Observer Variation | 1 | 2007 | 2593 | 0.010 |
Why?
|
ROC Curve | 1 | 2008 | 3527 | 0.010 |
Why?
|
Protein Subunits | 1 | 2003 | 959 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2007 | 2715 | 0.010 |
Why?
|
Phylogeny | 1 | 2007 | 2803 | 0.010 |
Why?
|
Computer Simulation | 1 | 2013 | 6196 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2011 | 3703 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2003 | 2839 | 0.010 |
Why?
|
Cell Line | 1 | 2012 | 15997 | 0.010 |
Why?
|
Cartilage | 1 | 2001 | 818 | 0.010 |
Why?
|
DNA, Mitochondrial | 1 | 2002 | 817 | 0.010 |
Why?
|
Biopsy | 1 | 2008 | 6756 | 0.010 |
Why?
|
Cell Division | 1 | 2003 | 4568 | 0.010 |
Why?
|
Meningeal Neoplasms | 1 | 2004 | 1241 | 0.010 |
Why?
|
Boston | 1 | 2008 | 9313 | 0.010 |
Why?
|
Pregnancy | 1 | 2016 | 29144 | 0.010 |
Why?
|
Ultrasonography | 1 | 2007 | 5985 | 0.010 |
Why?
|
Hypertension | 1 | 2014 | 8480 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2008 | 3843 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2016 | 15295 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2012 | 12072 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2018 | 13102 | 0.010 |
Why?
|
Logistic Models | 1 | 2008 | 13408 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2012 | 15519 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2008 | 13989 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2003 | 13815 | 0.010 |
Why?
|
Models, Biological | 1 | 2008 | 9583 | 0.010 |
Why?
|
Genetic Variation | 1 | 2007 | 6544 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2006 | 14722 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2002 | 4803 | 0.010 |
Why?
|
Physicians | 1 | 2008 | 4567 | 0.010 |
Why?
|
Adolescent | 1 | 2017 | 85781 | 0.010 |
Why?
|
Transcription Factors | 1 | 2003 | 12208 | 0.000 |
Why?
|
Mutation | 1 | 2003 | 29786 | 0.000 |
Why?
|